中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2070 records (took 0.227 seconds)

    Subcutaneous Port With Locking Member
    71.
    发明公开
    Subcutaneous Port With Locking Member 审中-公开

    公开(公告)号：US20230143477A1

    公开(公告)日：2023-05-11

    申请号：US17995198

    申请日：2021-04-02

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Ayesha Arzumand ,  Chris Tarapata ,  Marc Bellisario ,  Christel Hartshorn ,  Matthew J. Gunn ,  Chase Fetzer

    IPC: A61M39/02 ,  A61M39/04

    CPC classification number: A61M39/0208 ,  A61M39/04

    Abstract: A subcutaneous port assembly includes a base, a connector, a stem, a sealing element, and a locking member. The connector extends from a first end attached to the base to a distal end and includes an inner surface defining a socket having an inside diameter. The stem extends from the base and into the socket. The stem includes an outer surface having an outside diameter that is less than the inside diameter of the socket. The sealing element is disposed within the socket between the stem and the inner surface of the socket. The locking member has a plunger received within the socket from the distal end and having a terminal end facing the sealing element. The plunger is axially movable between a first position and a second position to selectively compress the sealing element within the socket.

    Treatment of prostate cancer
    78.
    发明授权
    Treatment of prostate cancer 有权

    公开(公告)号：US11583526B2

    公开(公告)日：2023-02-21

    申请号：US16998900

    申请日：2020-08-20

    Applicant: Myovant Sciences GmbH ,  Takeda Pharmaceutical Company Limited

    Inventor： Vijaykumar Reddy Rajasekhar ,  Brendan Mark Johnson ,  David B. MacLean ,  Lynn Seely ,  Paul N. Mudd, Jr.

    IPC: A61K31/517 ,  A61K31/4164 ,  A61P35/00 ,  A61K31/501 ,  A61K31/513 ,  A61K9/00 ,  A61K31/4166

    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

Patent Agency Ranking